Home > Healthcare > Biotechnology > Biopharma > Cancer Gene Therapy Market
Cancer Gene Therapy Market Size
- Report ID: GMI763
- Published Date: Apr 2024
- Report Format: PDF
Cancer Gene Therapy Market Size
Cancer Gene Therapy Market size was valued at USD 2.2 Billion in 2023 and is expected to reach USD 11.8 Billion by end of 2032, growing at a CAGR of 20.5% over the analysis period, driven by factors such as the rising global prevalence of cancer cases and the growing need for gene therapy.
The gene therapy is expected to develop into a viable substitute treatment for neoplastic illnesses and all forms of cancer as a result of recent breakthroughs in the field. For instance, in March 2021, the U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy designated for treating patients with multiple myeloma for patient which had not responded to initial treatment lines.
Cancer gene therapy is a type of treatment that involves using genes to treat or prevent cancer. This approach aims to manipulate the genetic material of cancer cells to inhibit their growth, induce cell death, or stimulate the immune system to target and destroy cancerous cells.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Cancer Gene Therapy Market Size in 2023: | USD 2.2 Billion |
| Forecast Period: | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR: | 20.5% |
| 2032 Value Projection: | USD 11.8 Billion |
| Historical Data for: | 2021 - 2023 |
| No. of Pages: | 150 |
| Tables, Charts & Figures: | 256 |
| Segments covered: | Type, Therapy, Product, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Frequently Asked Questions (FAQ) :
Cancer Gene Therapy Market Scope
